Axxcess Wealth Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Axxcess Wealth Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3,518	Closed	-$37.7K	–	946
2023 Q4	$37.7K	Hold	3,518	–	–	﹤0.01%	819
2023 Q3	$21.1K	Hold	3,518	–	–	﹤0.01%	791
2023 Q2	$24.3K	Hold	3,518	–	–	﹤0.01%	581
2023 Q1	$55.2K	Hold	3,518	–	–	﹤0.01%	624
2022 Q4	$70.4K	Sell	3,518 -875	-20%	-$17.4K	0.01%	599
2022 Q3	$78K	Hold	4,393	–	–	0.01%	528
2022 Q2	$98K	Hold	4,393	–	–	0.01%	518
2022 Q1	$122K	Buy	4,393 +875	+25%	+$31.8K	0.01%	612
2021 Q4	$160K	Buy	+3,518	New	+$237K	0.01%	601

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axxcess Wealth Management's ONCT Position: Q1 2024 in Review

Axxcess Wealth Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 3,518 shares — an estimated $37.7K sold.

Axxcess Wealth Management first reported a position in ONCT in Q4 2021 and held it in 9 quarters. The position peaked at $160K in Q4 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Axxcess Wealth Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Axxcess Wealth Management sold 3,518 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $37.7K.
Axxcess Wealth Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Axxcess Wealth Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $160K in Q4 2021.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Axxcess Wealth Management's 13F filing for Q1 2024, filed 14 May 2024.